2.50
Hdl Handle:
http://hdl.handle.net/10541/86502
Title:
Growth hormone and neurofibromatosis.
Authors:
Howell, Simon J; Wilton, Patrick; Lindberg, Anders; Shalet, Stephen M
Abstract:
Data collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated.
Affiliation:
Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Growth hormone and neurofibromatosis. 2000, 53 Suppl 1:70-6 Horm. Res.
Journal:
Hormone Research
Issue Date:
2000
URI:
http://hdl.handle.net/10541/86502
DOI:
10.1159/000053208
PubMed ID:
10895046
Type:
Article
Language:
en
ISSN:
0301-0163
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Simon Jen
dc.contributor.authorWilton, Patricken
dc.contributor.authorLindberg, Andersen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2009-11-19T15:38:34Z-
dc.date.available2009-11-19T15:38:34Z-
dc.date.issued2000-
dc.identifier.citationGrowth hormone and neurofibromatosis. 2000, 53 Suppl 1:70-6 Horm. Res.en
dc.identifier.issn0301-0163-
dc.identifier.pmid10895046-
dc.identifier.doi10.1159/000053208-
dc.identifier.urihttp://hdl.handle.net/10541/86502-
dc.description.abstractData collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated.en
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshBody Height-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshFemale-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeurofibromatoses-
dc.subject.meshOptic Nerve Glioma-
dc.subject.meshTreatment Outcome-
dc.titleGrowth hormone and neurofibromatosis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalHormone Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.